These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 6444305)

  • 1. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor.
    Sakata Y; Aoki N
    J Clin Invest; 1980 Feb; 65(2):290-7. PubMed ID: 6444305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis.
    Mimuro J; Kimura S; Aoki N
    J Clin Invest; 1986 Mar; 77(3):1006-13. PubMed ID: 2419360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis.
    Sakata Y; Aoki N
    J Clin Invest; 1982 Mar; 69(3):536-42. PubMed ID: 7199538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-linking of alpha 2-antiplasmin to fibrin is a key factor in regulating blood clot lysis: species differences.
    van Giezen JJ; Minkema J; Bouma BN; Jansen JW
    Blood Coagul Fibrinolysis; 1993 Dec; 4(6):869-75. PubMed ID: 7511944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of ancrod anticoagulation. A direct proteolytic effect on fibrin.
    Pizzo SV; Schwartz ML; Hill RL; McKee PA
    J Clin Invest; 1972 Nov; 51(11):2841-50. PubMed ID: 4263497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombomodulin-dependent effect of factor V Leiden mutation on the cross-linking of α2-plasmin inhibitor to fibrin and its consequences on fibrinolysis.
    Koncz Z; Bagoly Z; Haramura G; Mezei ZA; Muszbek L
    Thromb Res; 2012 Sep; 130(3):528-34. PubMed ID: 22704462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of alpha 2-plasmin inhibitor].
    Mimuro J; Aoki N
    Rinsho Byori; 1985 Feb; Spec No 61():97-105. PubMed ID: 2860263
    [No Abstract]   [Full Text] [Related]  

  • 8. Cross-linking of alpha 2-plasmin inhibitor and fibronectin to fibrin by fibrin-stabilizing factor.
    Tamaki T; Aoki N
    Biochim Biophys Acta; 1981 Oct; 661(2):280-6. PubMed ID: 7295739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor XIII-mediated cross-linking of NH2-terminal peptide of alpha 2-plasmin inhibitor to fibrin.
    Ichinose A; Tamaki T; Aoki N
    FEBS Lett; 1983 Mar; 153(2):369-71. PubMed ID: 6617867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-linking of alpha 2-plasmin inhibitor to fibrin catalyzed by activated fibrin-stabilizing factor.
    Tamaki T; Aoki N
    J Biol Chem; 1982 Dec; 257(24):14767-72. PubMed ID: 6129243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder.
    Kluft C; Nieuwenhuis HK; Rijken DC; Groeneveld E; Wijngaards G; van Berkel W; Dooijewaard G; Sixma JJ
    J Clin Invest; 1987 Nov; 80(5):1391-400. PubMed ID: 2445779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrin-fibrin and alpha 2-antiplasmin-fibrin cross-linking by platelet factor XIII increases the resistance of platelet clots to fibrinolysis.
    Reed GL; Matsueda GR; Haber E
    Trans Assoc Am Physicians; 1991; 104():21-8. PubMed ID: 1845147
    [No Abstract]   [Full Text] [Related]  

  • 13. Protransglutaminase (factor XIII) mediated crosslinking of fibrinogen and fibrin.
    Siebenlist KR; Meh DA; Mosesson MW
    Thromb Haemost; 2001 Nov; 86(5):1221-8. PubMed ID: 11816711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH; Diamond SL
    Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clottability and cross-linking reactivity of fibrin(ogen) following differential release of fibrinopeptides A and B.
    Furlan M; Seelich T; Beck EA
    Thromb Haemost; 1976 Dec; 36(3):582-92. PubMed ID: 14415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of substrate specificity for factor XIII.
    McDonagh J; Fukue H
    Semin Thromb Hemost; 1996; 22(5):369-76. PubMed ID: 8989819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defective alpha-polymerization in the conversion of fibrinogen Baltimore to fibrin.
    Brown CH; Crowe MF
    J Clin Invest; 1975 Jun; 55(6):1190-4. PubMed ID: 1133167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of fibrin-stabilizing factor on the subunit structure of human fibrin.
    Schwartz ML; Pizzo SV; Hill RL; McKee PA
    J Clin Invest; 1971 Jul; 50(7):1506-13. PubMed ID: 5090065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acceleration of fibrinolysis by the N-terminal peptide of alpha 2-plasmin inhibitor.
    Kimura S; Tamaki T; Aoki N
    Blood; 1985 Jul; 66(1):157-60. PubMed ID: 3159442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding of synthetic B knobs to fibrinogen changes the character of fibrin and inhibits its ability to activate tissue plasminogen activator and its destruction by plasmin.
    Doolittle RF; Pandi L
    Biochemistry; 2006 Feb; 45(8):2657-67. PubMed ID: 16489759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.